To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
The number of drugs being prescribed for people living with Parkinson’s in Scotland, UK, has increased by more than a quarter. National Health Service (NHS) figures, published by the Scottish Conservative party, show that the number of items being dispensed for the condition have leapt by 28% – from 260,355 in 2010 to 333,167 in 2019. The sharp rise is thought to be a consequence of Scotland’s ageing population and has prompted calls from bodies, including Parkinson’s UK, for government action to ensure the NHS can cope with the increasing number of Parkinson’s cases. Annie Macleod, director of Parkinson’s UK Scotland, said: “Over the next decade we expect to see numbers increase by a fifth.” She added that reasons for such a spike could include “growing numbers of people living with more complex Parkinson’s, or changes to the ways that specialists are managing Parkinson’s”.
Over a quarter of people living with Parkinson’s were initially misdiagnosed, study finds
More than a quarter of people living with Parkinson’s were initially misdiagnosed, according to new research from charity Parkinson’s UK. As part of the study, 2,000 people with Parkinson’s were asked a series of questions about their diagnosis. According to results, 26% of the participants were originally told they did not have Parkinson’s – with almost half of them being treated for a different condition. The poll also found that women were more likely to be misdiagnosed than men. Katie Goates, professional engagement manager at Parkinson’s UK, said: “One of the biggest challenges for Parkinson’s research is that there is no definitive test for Parkinson’s, and as a result we’ve heard of people being misdiagnosed with anything from a frozen shoulder or anxiety to a stroke. “Our survey has shown that because of this people are being left in limbo and seeing their health deteriorate, which is unacceptable.”
Queen Elizabeth II honours UK university for Parkinson’s research
A neuroscience research centre at the University of Sheffield, UK, has been recognised by Queen Elizabeth II for improving the lives of patients living with neurodegenerative conditions, including Parkinson’s. The Sheffield Institute for Translational Neuroscience, which is based at the university, uses emerging developments in neuroscience to create innovative new approaches to treating brain conditions. The prestigious Queen’s Anniversary Prize was awarded at St James’s Palace, London. The institute was commended for its development of Parkinson’s drug discovery programmes. The honour is awarded to UK universities who exhibit groundbreaking and innovative approaches to research – with beneficial results at local, national and global levels. Professor Koen Lamberts, president and vice-chancellor for the University of Sheffield, said: “As well as making life-changing discoveries today, The Sheffield Institute for Translational Neuroscience is nurturing the next generation of talented neuroscience students, whose research will lead to pioneering treatments for those living with neurological…